Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab.
Terranova N, French J, Dai H, Wiens M, Khandelwal A, Ruiz-Garcia A, Manitz J, von Heydebreck A, Ruisi M, Chin K, Girard P, Venkatakrishnan K. Terranova N, et al. Among authors: girard p. CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):333-347. doi: 10.1002/psp4.12754. Epub 2022 Jan 19. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34971492 Free PMC article. Clinical Trial.
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R. Xiong W, et al. Among authors: girard p. Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30. Cancer Chemother Pharmacol. 2022. PMID: 35771259 Free PMC article. Clinical Trial.
Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
Pantoja K, Lanke S, Munafo A, Victor A, Habermehl C, Schueler A, Venkatakrishnan K, Girard P, Goteti K. Pantoja K, et al. Among authors: girard p. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1371-1381. doi: 10.1002/psp4.12851. Epub 2022 Aug 5. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35852048 Free PMC article.
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P, Abler D, Guidi M, Girard P, Amato F, Vietti Violi N, Dietz M, Guignard N, Wicky A, Latifyan S, De Micheli R, Jreige M, Dromain C, Csajka C, Prior JO, Venkatakrishnan K, Michielin O, Cuendet MA, Terranova N. Courlet P, et al. Among authors: girard p. CPT Pharmacometrics Syst Pharmacol. 2023 Aug;12(8):1170-1181. doi: 10.1002/psp4.12983. Epub 2023 Jun 16. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37328961 Free PMC article.
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Grisic AM, Xiong W, Tanneau L, Jönsson S, Friberg LE, Karlsson MO, Dai H, Zheng J, Girard P, Khandelwal A. Grisic AM, et al. Among authors: girard p. Clin Cancer Res. 2022 Apr 1;28(7):1363-1371. doi: 10.1158/1078-0432.CCR-21-2662. Clin Cancer Res. 2022. PMID: 34921021 Free PMC article.
1,726 results